DCM
UTHR icon

Delpha Capital Management’s United Therapeutics UTHR Stock Holding History

Delpha Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-138
Closed -$20K – 1173
2017
Q4 		$20K Buy
+138
New +$17.5K 0.02% 786

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Delpha Capital Management's UTHR Position: Q1 2018 in Review

Delpha Capital Management sold out of United Therapeutics (UTHR) in Q1 2018, closing a stake of 138 shares — an estimated $20K sold.

Delpha Capital Management first reported a position in UTHR in Q4 2017 and held it in 1 quarter. The position peaked at $20K in Q4 2017. 374 funds tracked by Wall St. Rank hold UTHR as of Q1 2018.

  • Delpha Capital Management reported no remaining United Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 138 United Therapeutics shares in Q1 2018, an estimated $20K.
  • Delpha Capital Management first reported a position in United Therapeutics in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's United Therapeutics position peaked at $20K in Q4 2017.
  • 374 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.